WEBULL
WebtradeDownload

Bonesupport Holding (OM:BONEX) Q3 Earnings Sharpen Focus On Rich Valuation

Simply Wall St · 2d ago

Bonesupport Holding came into today on a strong run, with the share price up sharply over the past month and quarter, and trading on a rich P/E multiple of 77.1x. Q3 2026 results were just released, and the headline is clear. The specialist orthobiologics player produced SEK 408.8m in sales and SEK 92.4m in net income, reinforcing a profitability story that has been building over the past year.

The stock closed at SEK 319.8 after another volatile session. The latest quarter again highlighted expanding earnings and a 19.4% trailing net margin that challenges any view this is still a purely early stage growth story.

Love Bonesupport Holding’s profitability and 19.4% net margin, but uneasy about paying a 77.1x P/E for OM:BONEX at SEK 319.8? Compare it with stocks that pair quality earnings with sturdier balance sheets in our list of solid balance sheet and fundamentals stocks (204 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs Q3 2025): SEK 408.8m vs. SEK 294.1m (up about 39%)
  • Net Income (Q3 2026 vs Q3 2025): SEK 92.4m vs. SEK 34.5m (up about 168%)
  • Basic EPS (Q3 2026 vs Q3 2025): SEK 1.41 vs. SEK 0.52 (up about 171%)
  • Net Margin (TTM Q3 2026 vs prior TTM): 19.4% vs. 13.6% (wider profitability on a trailing 12 month basis)

Earnings grab the headline, but investors who care about what they are really paying for usually follow the cash that drops through the business over time. Bonesupport Holding’s latest report puts profits in the spotlight, while the underlying cash generation quietly frames what that stream might be worth.

On those cash flows alone, and using a discounted cash flow model rather than headline profit, the stock could be a solid 16% undervalued.

OM:BONEX Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
OM:BONEX Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

Bonesupport bullish story vs execution reality

The optimistic view leans heavily on Bonesupport Holding converting clinical momentum into broader everyday use in high value procedures.

"Although interest is emerging in revision arthroplasty, with early data from a pilot study at Charité and some surgeons already integrating CERAMENT G into routine practice, the company still needs larger, long duration clinical studies before usage can broaden meaningfully, which could delay a more material contribution to revenue and earnings from this segment."

Q3 highlights strong CERAMENT G driven U.S. and EUROW sales and a 34% adjusted operating margin. That shows orthopedic economics scaling, but revision arthroplasty and spine are not yet quantified growth pillars. As a result, the bullish diversification milestone still looks early stage.

Bear case on adoption and tariffs under the microscope

Skeptics focus on whether CERAMENT’s footprint can offset adoption friction, regulatory lag and tariff pressure without eroding Bonesupport Holding’s profitability story.

"Regulatory and reimbursement factors add uncertainty, including the shift of CERAMENT V to the FDA De Novo process and the gradual impact of a 50% U.S. tariff that management expects to reduce U.S. gross margin by about 0.8% by late 2026."

Q3 shows gross margin around 94% and adjusted operating margin in the mid 30s, even after early manufacturing cost and tariff effects. Management still expects an FDA decision for CERAMENT V around Q4 or Q1, so the feared margin squeeze has not yet meaningfully bitten into group economics.

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for.

Hunt For Mispriced Earnings Power

Bonesupport Holding’s latest quarter highlights how a strong profitability profile can still leave investors debating the right valuation. The real opportunity lies in spotting stocks that could be undervalued before tighter pricing closes the gap.

  • Company 1 - 46% below our estimate - expands sterile injectable capacity and uses in-house heparin sourcing to support higher margin contract manufacturing volumes.
  • Company 2 - 18% below our estimate - tightens headcount while growing secured retail lending so each branch carries more mortgages, gold loans and small business credit.
  • Company 3 - 23% below our estimate - scales manufacturing for incretin therapies as cardiometabolic and obesity treatments become the anchor for a broader drug portfolio.

That is three of the list. See every one of the 192 undervalued companies on it →